| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2500242 | Farmacia Hospitalaria | 2010 | 6 Pages |
Abstract
Authorisation according to the EMEA guidelines for biosimilars by centralized approval procedure, to demonstrate quality, efficacy and safety compared to the reference product Neupogen®. Comprehensive phase I and phase III clinical studies involving 880 subjects and patients have been completed (table 1).
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
P. GarcÃa Alfonso,